We may therefore hypothesize that, mirroring what happens during bone remodeling, dermal FBs, may play a role in modulating the angiogenic process occurring in normal skin and during SSc via EGFL7 secretion. The gene discussed is EGFL7; the disease is systemic sclerosis.